Published in N Engl J Med on July 16, 1970
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab (2008) 4.19
Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest (1976) 2.27
The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest (1971) 2.15
Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus. J Clin Invest (1972) 2.11
Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A (2010) 1.79
Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation (2008) 1.66
Glucagon secretion from the perfused rat pancreas. Studies with glucose and catecholamines. J Clin Invest (1974) 1.61
Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes (2010) 1.53
Secretion of glucagon from the isolated, perfused canine pancreas. J Clin Invest (1971) 1.47
Hyperglucagonemia of renal failure. J Clin Invest (1974) 1.45
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes (2010) 1.43
Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab (2010) 1.43
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism (2011) 1.41
Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest (1976) 1.40
The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes. J Clin Invest (1974) 1.39
Glucagon release induced by pancreatic nerve stimulation in the dog. J Clin Invest (1973) 1.35
Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab (2011) 1.32
Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology (2011) 1.32
Glucose modulation of amino acid-induced glucagon and insulin release in the isolated perfused rat pancreas. J Clin Invest (1974) 1.27
Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest (1972) 1.26
Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics. J Clin Invest (1975) 1.23
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest (2011) 1.20
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes (2009) 1.20
The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity. J Clin Invest (1973) 1.19
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
Identification of glucagon in the gastrointestinal tract. J Clin Invest (1975) 1.17
Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes (2012) 1.17
Human pancreatic exocrine response to nutrients in health and disease. Gut (2005) 1.16
The effect of alanine on glucagon secretion. J Clin Invest (1971) 1.14
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes (2011) 1.12
Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. Proc Natl Acad Sci U S A (1985) 1.12
Effect of insulin on muscle glutamate uptake. Whole blood versus plasma glutamate analysis. J Clin Invest (1972) 1.07
Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. J Clin Invest (1974) 1.06
Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol (2010) 1.06
Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes. BMC Genomics (2011) 1.05
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab (2016) 1.00
Insulin and glucose as modulators of the amino acid-induced glucagon release in the isolated pancreas of alloxan and streptozotocin diabetic rats. J Clin Invest (1975) 1.00
Suppressive effect of secretin upon pancreatic alpha cell function. J Clin Invest (1972) 0.97
Abnormal secretion of insulin and glucagon by the in vitro perfused pancreas of the genetically diabetic Chinese hamster. J Clin Invest (1974) 0.95
Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am J Physiol Endocrinol Metab (2011) 0.93
Can Roux-en-Y gastric bypass provide a lifelong solution for diabetes mellitus? Can J Surg (2009) 0.93
Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther (2010) 0.92
Alpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination? J Histochem Cytochem (2015) 0.91
Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care (2011) 0.91
Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. J Clin Biochem Nutr (2013) 0.91
Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab (2014) 0.90
Hormonal control of pancreatic endocrine and exocrine secretion. Gut (1972) 0.90
Basal alpha-cell up-regulation in obese insulin-resistant adolescents. J Clin Endocrinol Metab (2010) 0.89
Metabolic and hormonal effects of glucagon infusion in erythroblastotic infants. Arch Dis Child (1973) 0.89
The glycogenolytic activity of immunoreactive pancreatic glucagon in plasma. J Clin Invest (1971) 0.89
Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients. J Clin Invest (1979) 0.87
PKC stimulated by glucagon decreases UT-A1 urea transporter expression in rat IMCD. Pflugers Arch (2008) 0.85
Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes (2008) 0.84
Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol (2015) 0.84
Postprandial changes in portal haemodynamics in patients with cirrhosis. Gut (1992) 0.83
Alogliptin benzoate for management of type 2 diabetes. Vasc Health Risk Manag (2015) 0.83
Glucagon orchestrates stress-induced hyperglycaemia. Diabetes Obes Metab (2016) 0.82
Glucagon receptor antagonism induces increased cholesterol absorption. J Lipid Res (2015) 0.81
Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. J Diabetes Metab Disord (2015) 0.81
Fractalkine (CX3CL1), a new factor protecting β-cells against TNFα. Mol Metab (2014) 0.81
Glucagon: a "contaminant" comes of age. Can Med Assoc J (1971) 0.81
Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy. J Biol Chem (2012) 0.81
Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice. AAPS J (2009) 0.80
Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring In Silico Approach. Evid Based Complement Alternat Med (2015) 0.79
Effects of Obesity and Diabetes on α- and β-Cell Mass in Surgically Resected Human Pancreas. J Clin Endocrinol Metab (2016) 0.79
Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition. Proc Natl Acad Sci U S A (2017) 0.78
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag (2010) 0.78
β-cell mass in people with type 2 diabetes. J Diabetes Investig (2011) 0.78
Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function. J Clin Invest (1980) 0.78
Glucagonoma syndrome in a 19-year-old woman. West J Med (1978) 0.78
Glucagon and insulin have opposite effects on tissue chromium distribution in an obese mouse model. J Diabetes Investig (2013) 0.77
Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Ther Adv Endocrinol Metab (2014) 0.77
Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. J Diabetes Investig (2015) 0.76
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia. Diabetes (2011) 0.76
Plasma glucagon in diabetes of haemochromatosis: too low or too high? Gut (1979) 0.75
Glucagon: its significance in health and disease. Ulster Med J (1976) 0.75
Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin. Diabetologia (2016) 0.75
Role of histamine H3 receptor in glucagon-secreting αTC1.6 cells. FEBS Open Bio (2014) 0.75
Pancreatic endocrine function in cortisol-treated thyroidectomized calves. J Physiol (1981) 0.75
Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance. PLoS One (2016) 0.75
Glucagon and lipid signaling in the hypothalamus. Mamm Genome (2014) 0.75
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 4.74
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A (1998) 4.72
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci (1969) 3.42
Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A (1997) 3.07
The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest (1975) 2.97
Functional subdivision of islets of Langerhans and possible role of D cells. Lancet (1975) 2.83
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest (1968) 2.60
Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem (1998) 2.59
Glucagon levels and metabolic effects in fasting man. J Clin Invest (1970) 2.58
The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet (1975) 2.54
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest (1967) 2.53
Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest (1984) 2.52
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia (1985) 2.48
Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. J Clin Invest (1968) 2.46
Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest (1997) 2.45
Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem (1995) 2.43
Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med (1975) 2.30
The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest (1971) 2.15
Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc Natl Acad Sci U S A (1996) 2.15
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A (2000) 2.11
Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl J Med (1990) 2.01
Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes (1982) 1.94
Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A (1999) 1.92
Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation (2000) 1.91
Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med (1979) 1.88
Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes (1969) 1.86
Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes. Science (1990) 1.85
Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes (1971) 1.85
Physiology and pathophysiology of glucagon. Physiol Rev (1976) 1.79
A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med (1966) 1.79
Entero-insular axis. Arch Intern Med (1969) 1.74
The role of aminogenic glucagon secretion in blood glucose homeostasis. J Clin Invest (1969) 1.71
Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest (1968) 1.71
Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem (1970) 1.70
Control of pancreatic glucagon secretion by glucose. Diabetes (1969) 1.69
Glucagon physiology and pathophysiology in the light of new advances. Diabetologia (1985) 1.69
Novel form of lipolysis induced by leptin. J Biol Chem (1999) 1.67
Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes (1997) 1.66
Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med (1973) 1.66
Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med (1981) 1.66
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem (2000) 1.65
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A (1998) 1.64
Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med (1973) 1.62
Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci U S A (1997) 1.59
Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Natl Acad Sci U S A (1976) 1.59
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A (1999) 1.58
Hyperglucagonaemia after burns. Lancet (1974) 1.56
Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A (1998) 1.53
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. J Biol Chem (1996) 1.53
Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia (1995) 1.52
The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes (1976) 1.51
Evidence that down-regulation of beta-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci U S A (1990) 1.51
Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest (1992) 1.50
Transmission of leukaemia. Nature (1990) 1.49
More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling. Diabetes (1994) 1.45
Identification of a virulence-associated antigen of Toxoplasma gondii by use of a mouse monoclonal antibody. Infect Immun (1991) 1.45
Hyperglucagonemia of renal failure. J Clin Invest (1974) 1.45
Effects of secretin on insulin and glucagon in portal and peripheral blood in man. Lancet (1966) 1.44
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest (1969) 1.42
Meticulous control of diabetes: benefits, risks, and precautions. Diabetes (1982) 1.41
A novel leptin receptor isoform in rat. FEBS Lett (1996) 1.40
Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia (2004) 1.40
PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A (2002) 1.39
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem (1998) 1.39
The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes. J Clin Invest (1974) 1.39
Glucagon physiology and pathophysiology. N Engl J Med (1971) 1.38
Structural coupling between pancreatic islet cells. Experientia (1973) 1.37
The riddle of tumor hypoglycemia. Am J Med (1966) 1.35
Effect of secretin on insulin secretion. Lancet (1966) 1.35
Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism (1966) 1.35
Regulation of beta-cell glucose transporter gene expression. Proc Natl Acad Sci U S A (1990) 1.34
beta-cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes (1997) 1.33
Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. Trans Assoc Am Physicians (1966) 1.32
Half-life of somatostatin-like immunoreactivity in canine plasma. Endocrinology (1979) 1.32
Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: role in the pathogenesis of lipotoxic diabetes. Diabetes (1998) 1.31
Pronase effect on pancreatic beta cell secretion and morphology. Science (1973) 1.31
Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol (1997) 1.31
Active hepatic glycogen synthesis from gluconeogenic precursors despite high tissue levels of fructose 2,6-bisphosphate. J Biol Chem (1986) 1.29
Characterization of glucagon-like immunoreactivity (GLI). Diabetes (1970) 1.29
Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism (1978) 1.27
Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest (1972) 1.26
Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med (1978) 1.26
Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol (1978) 1.25